ArticleJournal of fluorescence2025
Systematically Investigating CRISPR/Cas12a Fluorescent Biosensor for Sensitive and Specific Single Nucleotide Variants Detection.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Precise identification and detection of single nucleotide variation (SNV) concomitant with excess wild-type DNA is greatly needed for invasive disease diagnosis, pathogens detection and early prediction of drug responsiveness. Many variants of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), notably the D614G and N501Y mutations, have been shown to significantly increase the infectivity of pandemics. We herein investigated CRISPR/Cas12a integrated three types fluorescent reporters and two crRNAs for SNV detection by taking D614G and N501Y variants of SARS-CoV-2 as model examples. We systematically screened all possible base substitutions from positions 0 to 19 and identified the middle position of crRNA could efficiently increase the specificity from both theoretical and experimental standpoints. With selected mutation location of crRNA, we then investigated the specificity of ssDNA, dsDNA and molecular beacon (MB) fluorescent reporters and proved the MB reporters can efficiently increase the discriminatory factors. Furthermore, we designed an additional mutation site on crRNA to increase the specificity. For user convenience, we engineered the lateral flow strips to present the results visualized with the naked eyes. Results of specific variants from Omicron proved the feasibility of clinical applications. These findings indicated that the proposed method is a powerful tool for monitoring the key mutations in pathogens and allows for modifications to incorporate newer upcoming variants.
Indexed as
Identifiers
40402429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.